NO2321351T3 - - Google Patents
Info
- Publication number
- NO2321351T3 NO2321351T3 NO09789161A NO09789161A NO2321351T3 NO 2321351 T3 NO2321351 T3 NO 2321351T3 NO 09789161 A NO09789161 A NO 09789161A NO 09789161 A NO09789161 A NO 09789161A NO 2321351 T3 NO2321351 T3 NO 2321351T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18935708P | 2008-08-18 | 2008-08-18 | |
PCT/US2009/004711 WO2010021697A2 (en) | 2008-08-18 | 2009-08-17 | Antibodies to ccr2 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2321351T3 true NO2321351T3 (no) | 2018-03-31 |
Family
ID=41347729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO09789161A NO2321351T3 (no) | 2008-08-18 | 2009-08-17 |
Country Status (22)
Country | Link |
---|---|
US (2) | US8710191B2 (no) |
EP (1) | EP2321351B1 (no) |
JP (1) | JP5685535B2 (no) |
KR (1) | KR101772706B1 (no) |
CN (1) | CN102239180B (no) |
AU (1) | AU2009283199B2 (no) |
BR (1) | BRPI0916973A2 (no) |
CA (1) | CA2734578C (no) |
CO (1) | CO6351802A2 (no) |
DK (1) | DK2321351T3 (no) |
ES (1) | ES2658117T3 (no) |
HK (1) | HK1163134A1 (no) |
IL (1) | IL211284A (no) |
MX (1) | MX2011001911A (no) |
MY (1) | MY160892A (no) |
NO (1) | NO2321351T3 (no) |
NZ (1) | NZ591471A (no) |
PE (1) | PE20110774A1 (no) |
RU (1) | RU2547595C2 (no) |
SG (2) | SG193216A1 (no) |
WO (1) | WO2010021697A2 (no) |
ZA (1) | ZA201101047B (no) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110038871A1 (en) * | 2009-08-11 | 2011-02-17 | Veena Viswanth | Ccr2 inhibitors for treating conditions of the eye |
EP2547366A4 (en) * | 2010-03-18 | 2013-08-07 | Univ Colorado State Res Found | INHIBITING AGENTS OF SUPPRESSIVE MYELOID CELLS |
EP2663330B1 (en) * | 2011-01-10 | 2019-03-06 | NovImmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
CN102603649B (zh) * | 2011-01-20 | 2016-05-25 | 赣南师范学院 | 一种以地巴唑为先导分子的荧光探针化合物及其制备方法 |
US20120288442A1 (en) * | 2011-05-11 | 2012-11-15 | Atomic Energy Council-Institute Of Nuclear Energy Research | Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis |
EP2718311B1 (en) | 2011-06-13 | 2018-01-17 | TLA Targeted Immunotherapies AB | Treating multiple sclerosis |
DK2718312T3 (en) | 2011-06-13 | 2018-10-15 | Tla Targeted Immunotherapies Ab | TREATMENT OF CONDITIONS CONNECTED WITH SEPSIS |
ES2801901T3 (es) | 2011-06-13 | 2021-01-14 | Tla Targeted Immunotherapies Ab | Tratamiento de afecciones asociadas al síndrome metabólico |
WO2012172339A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory arthritis |
WO2012172343A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating primary sclerosing cholangitis |
WO2012172336A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory skin diseases |
US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
WO2012172337A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating cardiovascular disease |
ES2821375T3 (es) | 2011-06-13 | 2021-04-26 | Tla Targeted Immunotherapies Ab | Tratamiento de afecciones respiratorias |
US20140349321A1 (en) * | 2011-12-16 | 2014-11-27 | Agency For Science, Technology And Research | Binding molecules against dengue virus and uses thereof |
WO2013192596A2 (en) | 2012-06-22 | 2013-12-27 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind ccr2 |
US8975290B2 (en) | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
MX2015012225A (es) * | 2013-03-13 | 2016-01-08 | Prothena Biosciences Ltd | Inmunoterapia tau. |
NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
WO2016081801A1 (en) * | 2014-11-21 | 2016-05-26 | Millennium Pharmaceuticals, Inc. | Use of an anti-ccr2 antagonist in the treatment of an infectious disease |
NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
EP3262418B1 (en) * | 2015-02-26 | 2019-05-01 | Innovative Concepts in Drug Development | Diagnostic markers of cognitive impairments, kits and uses thereof |
WO2017191561A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
PL3452507T3 (pl) | 2016-05-02 | 2023-01-09 | Prothena Biosciences Limited | Immunoterapia tau |
SG11201808434WA (en) | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
MX2018014743A (es) | 2016-06-03 | 2019-04-11 | Chemocentryx Inc | Metodo para tratar fibrosis hepatica. |
CA3044621A1 (en) | 2016-11-23 | 2018-05-31 | Chemocentryx, Inc. | Method of treating focal segmental glomerulosclerosis |
EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
US20200071417A1 (en) | 2017-04-19 | 2020-03-05 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
MX2019013045A (es) | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
SG11202002975YA (en) | 2017-10-11 | 2020-04-29 | Chemocentryx Inc | Treatment of focal segmental glomerulosclerosis with ccr2 antagonists |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
US20200377571A1 (en) | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
AU2018393076A1 (en) | 2017-12-19 | 2020-07-02 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
JP7330977B2 (ja) | 2017-12-19 | 2023-08-22 | スロゼン オペレーティング, インコーポレイテッド | Wntサロゲート分子及びその使用 |
BR112021000022A2 (pt) | 2018-07-03 | 2021-03-30 | Fennec Pharmaceuticals, Inc. | Formulações de tiossulfato de sódio anidro |
US20210317461A1 (en) | 2018-08-09 | 2021-10-14 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
WO2020069372A1 (en) | 2018-09-27 | 2020-04-02 | Elstar Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
CN113795508A (zh) | 2018-12-24 | 2021-12-14 | 赛诺菲 | 具有突变型Fab结构域的多特异性结合蛋白 |
EP3911954A4 (en) * | 2019-01-16 | 2022-11-02 | Yeda Research and Development Co. Ltd | BIOMARKERS FOR MODIFICATION OF CNS DISEASES |
SG11202108414UA (en) | 2019-03-03 | 2021-08-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
JPWO2020213665A1 (no) * | 2019-04-17 | 2020-10-22 | ||
US20220220212A1 (en) * | 2019-05-13 | 2022-07-14 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind ccr2 to modulate cellular function |
MX2021015882A (es) * | 2019-06-26 | 2022-04-18 | Amunix Pharmaceuticals Inc | Fragmentos de unión a antígeno egfr y composiciones que los comprenden. |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US20220025436A1 (en) * | 2020-07-21 | 2022-01-27 | Rutgers, The State University Of New Jersey | Method and Kit For CCR2 Expression Profiling And Disease Stratification |
WO2022097117A1 (en) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Ltd. | Antibody drug conjugates |
AU2022378899A1 (en) | 2021-10-27 | 2024-03-07 | Granite Bio Ag | Antibodies targeting ccr2 |
CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
RU2194760C2 (ru) | 1991-12-02 | 2002-12-20 | Кор Терапьютикс, Инк. | Иммуноглобулиновый полипептид, его фрагмент, композиция, штамм гибридных культивируемых клеток, способ получения полипептида |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
AU705616B2 (en) | 1995-04-21 | 1999-05-27 | Cell Genesys, Inc. | Generation of large genomic DNA deletions |
AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SE9600820D0 (sv) | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク. | 治療薬としてのcd147結合分子 |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
JP3793693B2 (ja) | 1998-12-23 | 2006-07-05 | ファイザー インコーポレーテッド | Ctla−4に対するヒトモノクローナル抗体 |
CA2399080C (en) | 2000-02-03 | 2013-05-21 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
US20030165988A1 (en) * | 2002-02-08 | 2003-09-04 | Shaobing Hua | High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins |
AR037456A1 (es) | 2001-11-30 | 2004-11-10 | Biogen Inc | Anticuerpos contra proteinas quimiotacticas monocitarias |
AU2003209059A1 (en) * | 2002-02-08 | 2003-09-02 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
US7202343B2 (en) | 2002-08-19 | 2007-04-10 | Abgenix, Inc. | Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof |
JP4426449B2 (ja) | 2002-09-12 | 2010-03-03 | 財団法人化学及血清療法研究所 | ヒト抗ヒトmcp−1抗体及び該抗体フラグメント |
MXPA06000176A (es) | 2003-12-10 | 2006-06-27 | Millennium Pharm Inc | Anticuerpos anti-ccr2 humanizados y sus metodos de uso. |
DK1753783T3 (en) | 2004-06-03 | 2014-11-17 | Novlmmune Sa | Anti-CD3 antibodies, and methods of use thereof |
US7371825B2 (en) | 2004-06-30 | 2008-05-13 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
RU2007103332A (ru) | 2004-07-30 | 2008-08-10 | Пфайзер Продактс Инк. (Us) | Способы лечения опосредуемых ccr2 заболеваний или нарушений |
BRPI0718225A2 (pt) | 2006-10-05 | 2013-11-12 | Centocor Ortho Biotech Inc | Antagonistas de ccr2 para tratamento de fibrose |
-
2009
- 2009-08-17 WO PCT/US2009/004711 patent/WO2010021697A2/en active Application Filing
- 2009-08-17 MX MX2011001911A patent/MX2011001911A/es active IP Right Grant
- 2009-08-17 CA CA2734578A patent/CA2734578C/en active Active
- 2009-08-17 MY MYPI2011000512A patent/MY160892A/en unknown
- 2009-08-17 JP JP2011523807A patent/JP5685535B2/ja active Active
- 2009-08-17 KR KR1020117006355A patent/KR101772706B1/ko active IP Right Grant
- 2009-08-17 EP EP09789161.8A patent/EP2321351B1/en active Active
- 2009-08-17 US US13/059,702 patent/US8710191B2/en active Active
- 2009-08-17 SG SG2013063318A patent/SG193216A1/en unknown
- 2009-08-17 PE PE2011000160A patent/PE20110774A1/es active IP Right Grant
- 2009-08-17 AU AU2009283199A patent/AU2009283199B2/en not_active Ceased
- 2009-08-17 DK DK09789161.8T patent/DK2321351T3/en active
- 2009-08-17 CN CN200980136307.1A patent/CN102239180B/zh not_active Expired - Fee Related
- 2009-08-17 RU RU2011110169/10A patent/RU2547595C2/ru active
- 2009-08-17 SG SG10201701323TA patent/SG10201701323TA/en unknown
- 2009-08-17 ES ES09789161.8T patent/ES2658117T3/es active Active
- 2009-08-17 NO NO09789161A patent/NO2321351T3/no unknown
- 2009-08-17 BR BRPI0916973A patent/BRPI0916973A2/pt not_active IP Right Cessation
- 2009-08-17 NZ NZ591471A patent/NZ591471A/xx unknown
-
2011
- 2011-02-09 ZA ZA2011/01047A patent/ZA201101047B/en unknown
- 2011-02-17 IL IL211284A patent/IL211284A/en active IP Right Grant
- 2011-03-11 CO CO11030038A patent/CO6351802A2/es active IP Right Grant
-
2012
- 2012-04-17 HK HK12103743.0A patent/HK1163134A1/xx not_active IP Right Cessation
-
2014
- 2014-04-03 US US14/244,167 patent/US9238691B2/en active Active